dc.creator Zhu, Lihua
dc.creator She, Zhi-Gang
dc.creator Cheng, Xu
dc.creator Guo, Jiao
dc.creator Zhang, Bing-Hong
dc.creator Li, Hongliang
dc.identifier.other https://doi.org/10.1016/j.cmet.2020.04.021 spa
dc.description.abstract Type 2 diabetes (T2D) is a major comorbidity of COVID-19. However, the impact of blood glucose (BG) control on the degree of required medical interventions and on mortality in patients with COVID-19 and T2D remains uncertain. Thus, we performed a retrospective, multi-centered study of 7,337 cases of COVID-19 in Hubei Province, China, among which 952 had pre-existing T2D. We found that subjects with T2D required more medical interventions and had a significantly higher mortality (7.8% versus 2.7%; adjusted hazard ratio [HR], 1.49) and multiple organ injury than the non-diabetic individuals. Further, we found that well-controlled BG (glycemic variability within 3.9 to 10.0 mmol/L) was associated with markedly lower mortality compared to individuals with poorly controlled BG (upper limit of glycemic variability exceeding 10.0 mmol/L) (adjusted HR, 0.14) during hospitalization. These findings provide clinical evidence correlating improved glycemic control with better outcomes in patients with COVID-19 and pre-existing T2D. spa
dc.publisher Cell Metabolism eng
dc.subject Blood glucose spa
dc.title Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes spa
dc.identifier.doi https://doi.org/10.1016/j.cmet.2020.04.021 spa